Companies › Shenzhen Kangzhe Biotechnology
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CMS-D002 Capsules | – | Phase 2 | Uterine Fibroids With Menorrhagia | Jan 2027 |
| CMS-D017 | – | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria, PNH | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07462780 | CMS-D017 | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria, PNH | Genitourinary | Nov 2026 |
| NCT07402369 | CMS-D002 Capsules | Phase 2 | Uterine Fibroids With Menorrhagia | Oncology | Jan 2027 |
No annotated target.
–
Biocity Biopharmaceutics Henan Genuine Biotech Everest Medicines (China) BioRay Pharmaceutical Kind Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.